Results 221 to 230 of about 3,363,784 (294)
Piezoelectric materials are reviewed as active platforms for medical ultrasound, bridging electromechanical fundamentals, transducer architectures, and biomedical applications. Material–device co‐design is emphasized as the key to high‐performance diagnosis, therapy, monitoring, wearable ultrasound, and emerging ultrasound‐responsive functions ...
Jianan Li, Qing Wan
wiley +1 more source
Comment on 'Reducing complexity in International Bladder Cancer Group intermediate-risk non-muscle-invasive bladder cancer stratification: a three-factor approach'. [PDF]
Zhang B, Wang C, Shang P.
europepmc +1 more source
Living at genetic risk: The patient experience of Lynch syndrome
Abstract Lynch syndrome is a germline cancer predisposition syndrome caused by a variant in one of four genes. Lynch syndrome places individuals at significantly higher risk for a range of cancers, especially colorectal and endometrial. Depending on which gene is affected, the risk of ovarian, gastric, small bowel, pancreatic, biliary urothelial, brain,
Nicola Reents +2 more
wiley +1 more source
Abstract Lynch syndrome (LS) is the most common hereditary colorectal cancer syndrome, caused by a germline pathogenic variant in one of the mismatch repair (MMR) genes. Among these, MSH6‐associated LS represents a distinct subtype with unique molecular and clinical characteristics.
Salwa Ben Yahia +4 more
wiley +1 more source
SnoRNA and SNHG in Bladder Cancer: Molecular Mechanisms and Clinical Significance. [PDF]
Gimalova G +3 more
europepmc +1 more source
ABSTRACT Somatostatin receptors (SSTR) mediate the antiproliferative, antisecretory, and proapoptotic effects of somatostatin and its synthetic analogs. Their surface expression on neuroendocrine tumor (NET) cells is required for somatostatin analog therapy and radiopharmaceutical therapy (RPT).
Neeraj Kumari +10 more
wiley +1 more source
A NEK2/ZWINT-NDC80 regulatory axis drives bladder cancer progression and chemoresistance. [PDF]
Hu X +23 more
europepmc +1 more source
ABSTRACT This multicenter retrospective study evaluated the impact of type 2 diabetes mellitus (DM) on clinical outcomes and immune‐related adverse events (irAEs) in 450 patients with metastatic non‐small cell lung cancer (NSCLC) treated with second‐line nivolumab at 17 centers between 2016 and 2024. Among these patients, 118 (26.2%) had DM.
Emre Çakır +32 more
wiley +1 more source

